Biocon announced a settlement with Regeneron and Bayer under which it can launch its Yesafili® (aflibercept), biosimilar to Regeneron’s Eylea®, in Canada from 1 July 2025. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canda involving six patents relating to aflibercept. The settlement does not appear to have resolved disputes beyond Canada, there being no impact to the ongoing US aflibercept dispute between Biocon and Regeneron.
Yesafili® was granted tentative approval by Health Canada in March 2023, subject to resolution of patent issues. Yesafili® was approved in the UK in November 2023 and in EU in September 2023.